Imunon (NASDAQ:IMNN – Get Free Report) and NovelStem International (OTCMKTS:NSTM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Profitability
This table compares Imunon and NovelStem International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Imunon | N/A | -405.07% | -158.41% |
| NovelStem International | -26,941.67% | N/A | -61.08% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Imunon and NovelStem International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Imunon | 0 | 2 | 1 | 1 | 2.75 |
| NovelStem International | 0 | 0 | 0 | 0 | 0.00 |
Institutional and Insider Ownership
4.5% of Imunon shares are owned by institutional investors. 6.0% of Imunon shares are owned by insiders. Comparatively, 13.6% of NovelStem International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Imunon and NovelStem International”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Imunon | $500,000.00 | 31.67 | -$18.62 million | ($12.95) | -0.50 |
| NovelStem International | $10,000.00 | 84.38 | -$3.23 million | $0.01 | 1.80 |
NovelStem International has lower revenue, but higher earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than NovelStem International, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Imunon has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, NovelStem International has a beta of 2.24, indicating that its stock price is 124% more volatile than the S&P 500.
Summary
NovelStem International beats Imunon on 8 of the 15 factors compared between the two stocks.
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
About NovelStem International
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
